

Applicant : John E. Edwards, Jr. et al.
Appl. No. : 09/715,876
Examiner : Sarvamangala J N Devi
Docket No. : 13361.4001

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-12. (Cancelled)

13. (New) A pharmaceutical composition comprising a biocompatible carrier for injection or infusion and an isolated and purified N-terminal fragment of agglutinin-like sequence (ALS1) cell surface adhesin protein of *Candida albicans*, wherein the N-terminal fragment is encoded by a nucleotide sequence consisting of nucleotides 52 to 1296 of SEQ ID NO: 7 and wherein the composition produces antibodies that bind specifically to said ALS1 cell surface adhesin protein.

14. (New) The composition of claim 13, wherein the N-terminal fragment contains the binding site of the ALS1 cell surface adhesin protein.

15. (New) A pharmaceutical composition consisting essentially of a biocompatible carrier for injection or infusion and an isolated and purified N-terminal fragment of agglutinin-like sequence (ALS1) cell surface adhesin protein of *Candida albicans*, wherein the N-terminal fragment is encoded by a nucleotide sequence consisting of nucleotides 52 to 1296 of SEQ ID NO: 7 and wherein the composition produces antibodies that bind specifically to said ALS1 cell surface adhesin protein.

16. (New) The composition of claim 15, wherein the N-terminal fragment contains the binding site of the ALS1 cell surface adhesin protein.